aXichem publishes prospectus in connection with the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, EITHER DIRECTLY OR INDIRECTLY, WITHIN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATIONS OR OTHER MEASURES NOT STIPULATED BY SWEDISH LAW.
aXichem AB (publ) (”aXichem” or the ”Company”) has produced an EU Growth Prospectus in Swedish (the ”Prospectus”) relating to the rights issue of shares announced on 23 February 2023 (the “Rights Issue”).
The Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority (the “SFSA”). The Prospectus is available on aXichem’s website (www.axichem.com) and Västra Hamnen Corporate Finance AB’s website (www.vhcorp.se). The Prospectus will also be available on the SFSA’s website (www.fi.se).
Financial advisers, legal advisers and issuing agent
Västra Hamnen Corporate Finance AB acts as financial adviser and Vinge acts as legal adviser to aXichem in connection with the rights issue. Nordic Issuing acts as issuing agent.
For further information:
Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355. Email: [email protected]
Or visit: www.axichem.com
Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
The information was submitted, through the agency of the contact person, for publication on March 3, 2023, at 9:30 AM CET.
aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio-enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. More information is available at www.axichem.com.
Release, publication, or distribution of this press release may be subject to restrictions in certain jurisdictions. Recipients of this press release in the jurisdictions where this press release has been released, published, or distributed should inform themselves of and comply with such restrictions.
This press release does not constitute an offer to, or an invitation to, acquire or subscribe for any securities in aXichem in any jurisdiction. The invitation to interested persons to participate in the Rights Issue will only take place through the Prospectus that the Company will publish in connection with the Rights Issue.
This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the U.S. Securities Act of 1933. The information in this press release may not be disclosed, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea, or any other jurisdiction where such disclosure, publication or distribution of this information would be contrary to applicable laws and regulations.
Within the European Economic Area, no offer to the public of securities is made in any country other than Sweden. In other member states of the European Union, such an offer can only be made in accordance with exceptions in the Prospectus Regulation (EU) 2017/1129.
This press release contains certain forward-looking information that reflects the Company's current view of future events as well as financial and operational development. Words such as "intends", "estimates", "expects", "may", "plans", "believes", "estimates" and other expressions that imply indications or predictions of future developments or trends, and are not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties because it is dependent on future events and circumstances. Forward-looking information is not a guarantee of future performance or development, and actual outcomes may differ materially from what is stated in forward-looking information.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutraceuticals and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Västra Hamnen Corporate Finance, www.vhcorp.se. Read more about aXichem at www.axichem.se
Studie med gentestet Prostatype® publicerat i ledande internationell tidskrift
Studien som genomförts av ett forskningsteam på Akademiska sjukhuset i Uppsala under ledning av docent och överläkare Michael Häggman visar att gentestet Prostatype® korrekt bedömer prostatacancertumörens aggressivitet när man jämför genuttryck från vävnadsprover, så kallade biopsier, med ”fac...
ViroGates announces its Annual Report 2022: Growing revenue by 33% and more than tripling the customer base in clinical routine
BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, announces its Annual Report for the period 1 January – 31 December 2022, as approved today by the company’s Board of Directors....
AegirBio AB: Atlas Special Opportunities, LLC calls for partial conversion of outstanding convertible bonds to a nominal amount of MSEK 10.00
On 20 December 2022 AegirBio AB (“AegirBio” or the “Company”) announced that the Company had agreed on a convertible financing agreement with Atlas Special Opportunities, LLC (“Atlas”) regarding convertible bonds amounting to MSEK 55.00 (the “Convertible Bonds”) with attached warrants. On 20Ja...
AegirBio AB: Atlas Special Opportunities, LLC påkallar partiell konvertering av utestående konvertibler till ett nominellt belopp om 10,00 MSEK
Den 20 december 2022 meddelade AegirBio AB (”AegirBio” eller ”Bolaget”) att Bolaget avtalat om en konvertibelfinansiering med Atlas Special Opportunities, LLC (”Atlas”) avseende konvertibler om 55,00MSEK (”Konvertiblerna”) med vidhängande teckningsoptioner. Bolagsstämman beslutade den 20...